Editor's Pick
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
High tumor-specific mRNA levels were associated with increased risk of disease progression in 6,590 patient tumors across 15 cancer types.
New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur
Premium
Investigators shared results of a study this week in which ctDNA residual disease testing gave advance notice of late recurrences in surgically resected HR+ HER2- patients.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.
Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests
Tests like MDxHealth's SelectMDx, Bio-Techne's ExoDx Prostate, and various PSA scoring algorithms would be reimbursed if they pass a technical assessment.